MSH|^~\&|LAB|HOU||2135800|20050915174948||ORU^R01|20050915785887650000|D|2.4||||||code1~code2|PID|1||HL007545P~ID2||TEST^CASE2||19800801|M||||||||||0007111|||||||||||||OBR|1|0007111|HL007545P|6517SBX=^MICROALBUMIN/CREATININE RATIO, RANDOM URINE ^^6517SBX=^MICROALBUMIN/CREATININE RATIO, RANDOM URINE |||20050912100000|||||||20050912112200||B95594^UNKNOWN^UNKNOWN^||||^^^8459SB=^CREATININE, RANDOM URINE|HL^UNKNOWN DIAGNOSTICS-SOMEWHERE^8933 SOMETHING DR^SOMEWHERE^TX^77054|20050914130800|||F|||||||||||||||||||OBX|1|NM|25026500^CREATININE, RANDOM URINE^^25026500^CREATININE, RANDOM URINE^||100~200~300|MG/DL|20-370|N|||F|||20050914130800|HL^^L|||OBR|2|0007111|HL007545P|6517SBX=^^^6517SBX=^|||20050912100000|||||||20050912112200||B95594^UNKNOWN^UNKNOWN^||||^^^%SB6517^MICROALBUMIN/CREATININE RATIO, RANDOM URINE|HL^UNKNOWN-SOMEWHERE^8933 SOMETHING DR^SOMEWHERE^TX^77054|20050914130800|||F|||||||||||||||||||OBX|1|NM|50060710^MICROALBUMIN^^50060710^MICROALBUMIN^||400|MG/DL|||||F|||20050914130800|HL^^L|||OBX|2|NM|50061100^MICROALBUMIN/CREATININE RATIO, RANDOM URINE^^50061100^MICROALBUMIN/CREATININE RATIO, RANDOM URINE^||4|MCG/MG CREAT|<30|N|||F|||20050914130800|HL^^L|||NTE|1|| |NTE|2||    MICROALBUMIN/CREATININE RATIO IS USED TO CLASSIFY|NTE|3||PATIENTS AS BEING NORMAL (<30 MCG/MG CREATININE), HAVING |NTE|4||MICROALBUMINURIA (30-300 MCG/MG CREATININE), OR HAVING |NTE|5||CLINICAL ALBUMINURIA (>300 MCG/MG CREATININE).|NTE|6|| |NTE|7||    THE AMERICAN DIABETES ASSOCIATION POSITION STATEMENT|NTE|8||ON DIABETIC NEPHROPATHY STATES THAT MICROALBUMINURIA IS |NTE|9||PRESENT IF THE MICROALBUMIN/CREATININE RATIO EXCEEDS 30 |NTE|10||MCG/MG CREATININE. THE THRESHOLD FOR CLINICAL ALBUMINURIA|NTE|11||IS REACHED AT 300 MCG/MG CREATININE. THE CLASSIFICATION OF|NTE|12||A PATIENT SHOULD BE BASED UPON AT LEAST 2 OF 3 ABNORMAL|NTE|13||RESULTS ON SPECIMENS COLLECTED WITHIN A 3 TO 6 MONTH TIME|NTE|14||FRAME.|NTE|15|| |NTE|16||REFERENCE:|NTE|17|| |NTE|18||AMERICAN DIABETES ASSOCIATION, POSITION STATEMENT, DIABETIC |NTE|19||NEPHROPATHY, DIABETES CARE, 20, SUPPLEMENT 1, S24-S27, 1997.|NTE|20|| |